SWP
ALNY icon

Sagespring Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sagespring Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Sell
888
-256
-22% -$77.2K ﹤0.01% 734
2026
Q1 		$379K Buy
1,144
+8
+0.7% +$2.72K 0.01% 575
2025
Q4 		$452K Sell
1,136
-151
-12% -$66.8K 0.01% 503
2025
Q3 		$587K Buy
1,287
+371
+41% +$151K 0.01% 425
2025
Q2 		$299K Buy
+916
New +$253K 0.01% 582

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sagespring Wealth Partners's ALNY Position: Q2 2026 in Review

Sagespring Wealth Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q2 2026, selling an estimated $77.2K and leaving 888 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #734.

Sagespring Wealth Partners first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $587K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sagespring Wealth Partners held 888 shares of Alnylam Pharmaceuticals worth $267K as of Q2 2026.
  • Sagespring Wealth Partners sold 256 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $77.2K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Sagespring Wealth Partners's portfolio in Q2 2026, its #734 holding.
  • Sagespring Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Sagespring Wealth Partners's Alnylam Pharmaceuticals position peaked at $587K in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sagespring Wealth Partners's 13F filing for Q2 2026, filed 3 Aug 2026.